Baseline CXCL10 and CXCL13 levels are predictive biomarkers for tumor necrosis factor inhibitor therapy in patients with moderate to severe rheumatoid arthritis: a pilot, prospective study.

Arthritis Res Ther · 2016 · PMC4840903 · PMID 27102921

Europe PMC DOI

hedged sentence

0.2000

closest p · 4.0× alpha

0.2000

boldest claim

The sentences

did not reach statistical significancep = 0.20not close (p > 0.1)

Among patients who were treated with etanercept (n = 7), CXCL13 levels were higher in responders ( p = 0.045), and CXCL10 levels were numerically higher in responders, but the difference did not reach statistical significance ( p = 0.20).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.